One preclinical study demonstrated that fluorophore-conjugated anti-CEA antibodies specifically targeted CEA-expressing tumors in patient-derived orthotopic xenografts (PDOX) and orthotopic cancer cell-line mouse models [12]. This evidence concerns the gene CEACAM5 and cancer.